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Abstract
Background: A majority of primary ovarian neoplasms arise from cell surface epithelium of the
ovaries. Although old age and a positive family history are associated risk factors, the etiology of
the epithelial ovarian tumors is not completely understood. Additionally, knowledge of factors
involved in the histogenesis of the various subtypes of this tumor as well as those factors that
promote progression to advanced stages of ovarian malignancy are largely unknown. Current
evidence suggests that mitochondrial alterations involved in cellular signaling pathways may be
associated with tumorigenesis.
Methods: In this study, we determined the presence of polymorphisms and other sequence
variants of mitochondrial DNA (mtDNA) in 102 epithelial ovarian tumors including 10 matched
normal tissues that paired with some of the tumors. High-resolution restriction endonucleases and
PCR-based sequencing were used to assess the mtDNA variants spanning 3.3 kb fragment that
comprised the D-Loop and 12S rRNA-tRNAphe, tRNAval, tRNAser, tRNAasp, tRNAlys, ATPase 6,
ATPase 8, cytochrome oxidase I and II genes.
Results: Three hundred and fifty-two (352) mtDNA sequence variants were identified, of which
238 of 352 (68%) have not been previously reported. There were relatively high frequencies of
three mutations in the 12S rRNA gene at np 772, 773, and 780 in stage IIIC endometrioid tumors,
two of which are novel (773delT and 780delC), and occurred with a frequency of 100% (7/7).
Furthermore, two mutations were observed in serous tumors only at np 1657 in stage IV (10/10),
and at np 8221delA in benign cystadenomas (3/3) and borderline tumors (4/4). A high frequency,
81% (13/16) of TC insertion at np 310 was found only in early stages of serous subtype (benign
cystadenomas, 3/3; borderline tumors, 4/4; stage I tumors, 2/5 and matched normal tissues 4/4).
Conclusion: Our findings indicate that certain mtDNA mutations can reliably distinguish the
different histologic subtypes of epithelial ovarian tumors. In addition, these data raise the possibility
that certain mtDNA mutations may be useful biomarkers for predicting tumor aggressiveness and
may play a potential role in tumorigenesis.
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Background
Epithelial ovarian cancer is the fifth leading cause of can-
cer mortality among women in the United States [1]. The
majority (80–90%) of benign and malignant ovarian
tumors originate from the surface epithelium, even
though all cell types of the human ovary may undergo
neoplastic transformation [2,3]. Most of the histopatho-
logical differences that are reflected as serous, endometri-
oid, mucinous, clear cell, and transitional cell types of
ovarian cancer cannot be clearly explained by the presence
or absence of specific genetic changes [4]. Ovarian cancer
is notoriously difficult to diagnose in its early stages. Con-
sequently, approximately 90% of the patients with epithe-
lial ovarian cancer are diagnosed with metastasis to the
pelvis and upper abdomen and, for these patients, five
year survival rates are less than 30% [1]. In contrast, the
small proportion of patients diagnosed with stage I ovar-
ian cancer (confined to the ovaries) have a five year sur-
vival rate in excess of 90% [1]. Even when patients with
the same stage and histologic type of ovarian cancer are
considered, the biologic factors that could predict disease
behavior are not well understood. Thus, there is a pressing
need to identify ways to distinguish and understand the
different epithelial ovarian tumor subtypes in order to
develop effective treatment strategies.
Human mitochondrial gene mutations have increasingly
been associated with various cancers but with unclear
pathophysiological significance [3,5-9]. Most mtDNA
mutations occur in coding sequences because mtDNA
lacks introns. The mitochondrial genome is more vulner-
able to oxidative damage and undergoes a higher rate of
mutation than does the nuclear genome [10,11]. Some of
the mitochondrial genome aberrations found in cancer
tissues are mutations in mtDNA-encoded Complexes I,
III-V as well as mutations in the hypervariable regions [9].
MtDNA mutations in tumor cells are consistent with pre-
vious reports that tumor cells are subject to constitutive
oxidative stress [9,11,12]. Although most of the reported
mtDNA mutations in cancer are homoplasmic polymor-
phisms which are considered too subtle to cause any effect
on oxidative phosphorylation (OXPHOS), long-term
accumulation of subtle difference in OXPHOS activity
may eventually result in oxidative stress [12,13]. Conse-
quently, variations in the mtDNA may potentially play a
role as a modifying risk factor in the development of age
related diseases such as ovarian cancer. Mitochondrial
aberrations have been identified in tumors of colorectal,
breast, head and neck, kidney, lung, stomach and in the
hematologic malignancies, leukemia and lymphoma
[7,13-20]. Hence, we sought to determine the impact of
mtDNA sequence variants in the pathogenicity of epithe-
lial ovarian tumor subtypes.
Here we report the identification of mtDNA sequence var-
iants in multiple specimens of ovarian carcinoma using a
high-resolution restriction endonucleases and PCR-based
sequencing analyses. We have found several highly fre-
quent mtDNA sequence variants that could differentiate
the three major histopathological subtypes and stages of
serous, endometrioid and mucinous carcinomas of the
ovary.
Methods
Subjects
One hundred and two frozen epithelial ovarian tumor tis-
sues from three histologic subtypes (serous n = 42;
endometrioid, n = 33; mucinous n = 17), each of the
stages I-IV, benign cystadenomas, borderline tumors and
10 matched normal tissues that paired with the tumors
were obtained from Southern Regional Cooperative
Human Tissue Network and University of Alabama-Bir-
mingham (UAB)-Ovarian Spore Center. The ovarian
tumor subtypes and stages were histopathologically deter-
mined on the basis of the criteria outlined by the Interna-
tional Federation of Gynecology and Obstetrics (FIGO).
All studies were implemented under Morehouse School of
Medicine and UAB Institutional Review Board approval
protocols. MtDNA was isolated from the frozen tissues
using centrifugation method according to the manufac-
turer's protocols (BioVision, Research Products). Total
mtDNA was quantified and diluted to 50 ng/μl for PCR
reaction.
High Resolution Restriction Endonucleases and PCR-based 
Analysis of mtDNA variants
Extracted mtDNA from each tissue sample was PCR
amplified using two large sets of overlapping primers. The
first primer sets (for-5'-CCGGGCCCATAACACTTGGG-3',
position 16,453→16,472 in MITOMAP and rev-5'-
GGAGTGGGTTTGGGG CTAGG-3' 1,696→1,677) yielded
1.8 kb fragment that flank the D-loop and part of 12 rRNA
regions and the second primer sets (for-5'-GGAT-
GCCCCCCACCCTACC-3', 7,392→7,410 and rev-5'-CCTT-
GTGGTAAGAAGTGGGC-3', 8921-8902) yielded 1.5 kb
fragments that spanned part of cytochrome oxidases I, II
(COX I and II), ATPase 8 and ATPase 6 regions, which
have been previously described [21,22]. The tRNAs
enclosed in these regions are: Phe, Val, Ser, Asp, and Lys.
The PCR was performed with 35 cycles of denaturation at
94°C for 1 minute, annealing at 59°C for 1 minute and
extension at 72°C for 1 minute, and with the second set
of primers, the annealing was 62°C for 1 minute. Ampli-
fied fragments were then purified using the QIAquick
(QIAGEN) gel extraction kit. Each PCR product was
digested with 14 restriction endonucleases (AluI, AvaII,
BamHI, DdeI, HaeII, HaeIII, HhaI, HincII, HinfI, HpaI,
MspI, MboI, RsaI, and TaqI) and were electrophoresis-gel
analyzed side-by-side. Any mtDNA PCR fragments show-Journal of Carcinogenesis 2007, 6:1 http://www.carcinogenesis.com/content/6/1/1
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ing differences in banding patterns between subtypes,
stages of tumor and matched normal tissue samples were
first directly sequenced to identify the exact nature of the
new length variants detected by restriction analysis. Addi-
tionally, all the amplified products were sequenced with
the same PCR primer sets, to assess the presence of other
mtDNA mutations within the samples. PCR products
were sequenced using ABI PRISM 310 Genetic Analyzer
(Perkin-Elmer, Foster, CA).
Analysis of the mtDNA Sequences
The results of the mtDNA sequence analysis were com-
pared with the published NCBI sequence (Accession #
J01415). Furthermore, the sequence variants were com-
pared with those in the mtDNA databank [3] to verify if
the changes detected have previously been reported.
Sequence alignment among subtypes and within stages
were performed using Vector NTI advance 10-Align X pro-
gram (Invitrogen). MtDNA sequence variants present in
both the tumor and matched normal tissue were scored as
germ-line variants. Any mtDNA sequence variant that
were different between the tumor and the matched nor-
mal tissues were scored as somatic mutations. All
sequence variants were confirmed by repeated analysis of
the mtDNA extracted from the study samples.
Results and Discussion
The restriction analyses identified a number of band shifts
indicating site gains or losses between and among ovarian
subtypes and stages. However, these bands only indicated
that the predicted sequence had changed. They did not
identify specific base pair changes. We, therefore, used the
original primers to sequence the band shifts in order to
identify these specific changes. Among 102 ovarian tumor
samples (including 10 paired tumor and matched normal
tissues) that were sequenced, a total of three hundred and
fifty-two (352) mtDNA variants were observed over a
span of 3.3 kb fragment, including D-Loop, 12S rRNA-
tRNAphe, tRNAval, COX I, tRNAser, tRNAasp, COX II, tRNA-
lys, ATPase 6 and ATPase 8 (see additional file 1) and 238
of 352 (68%) were not previously reported [23]. Inser-
tions and deletions accounted for 38.3% (135/352) of the
observed mtDNA sequence variants suggesting instability
of mtDNA in epithelial ovarian tumors and is consistent
with previous studies by Gomez-Zaera et al., [6] and Vega
et al., [19]. A high frequency of mtDNA mutations among
our study samples, which have been previously reported
[23] were apparent at np A263G (93/102), A1438G (95/
102), A8860G (96/102) as shown in Table 1 and addi-
tional file 1. Also, there were high incidences (86–100%)
1648delT, T1653A/delT, 1659delT mtDNA sequence vari-
ants among the three epithelial ovarian tumor subtypes
and stages compared with 100 human genome sequences
[24] (Figure 1). MtDNA sequence variants T16519C,
A73G and A263G were found at frequencies of 36%–95%
among our samples and these variants have been
observed in various ethnic groups and other cancers [25].
A polymorphism, T16519C, has previously been shown
to significantly increase breast cancer risk [26].
Consistent with other studies, we have observed the inci-
dence of the polynucleotide repeat sequence at np 303–
315, which has already been reported as a mutational
hotspot D310, in a wide variety of human neoplasms
[14,27-32]. The number of cytosine residues in the first
stretch varied from C6-10T followed by the second stretch
of C5-6 (Figure 2A). The reference sequence (mitomap-
J01415) of this hot spot was C7TC5 and that of the gen-
eral population with NCBI Blast Search was C7-8TC6
[33].
The c-stretch instability at np 303–315 was observed in
97% of the study samples, including the 10 tumor sam-
ples that paired with the matched normal tissues. This
finding suggests that the observed c-stretch variants in
ovarian tumors are germline origin. The instability at np
303 has been observed in some premalignant lesions of
head and neck [16] and early stages of ovarian carcinomas
[34], although none of the associations in those studies
reached statistical significance. Perhaps the most striking
observation was the incidence of TC insertion at np 310
found at a relatively high frequency of 81% (13/16) only
in the early stages of serous subtype, which included
benign cystadenomas 3/3, borderline tumors 4/4, stage I
tumors 2/5, and matched normal tissues 4/4. While we
could not conclusively rule-in poly C and the TC insertion
instabilities as a major factor in the predominant subtype
of epithelial ovarian tumorigenesis, certainly, the weight
of the evidence, in spite of the limited sample size was not
against it.
Different mechanisms have been put forward to explain
the genomic instability of this stretch of cytosine residues
[34-37]. The relative proportion of variable length polyC
tracts appears to be actively maintained during cell divi-
sion despite evidence of random mtDNA segregation, sug-
gesting denovo regeneration of specific pattern following
cell division by unknown molecular mechanisms [38,39].
It is unclear if this instability is associated with ethnicity,
heredity or tissue specificity. Therefore, it is tempting to
explore the significance of this D310 hot spot as a biomar-
ker in detection, differentiation and progression of the
various subtypes and stages of ovarian tumors.
Interestingly, we did observe three mtDNA mutations in
the 12S rRNA gene at np A772T, 773delT, and 780delC in
endometrioid stage III tumors, of which 773delT (7/7)
and 780delC (7/7) with a frequency of 100% in endome-
trioid stage IIIC has not been reported. Furthermore, two
mutations of interest were observed only in serous sub-Journal of Carcinogenesis 2007, 6:1 http://www.carcinogenesis.com/content/6/1/1
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Table 1: High frequency mtDNA variants among three epithelial ovarian tumor subtypes
Mitochondrial genes/regions Nucleotide Position np Mutation Frequency
Total # of cases 102
% frequency in subtypes
Serous Endometrioid Mucinous
D-loop 16487 del A1 73 87 69 39
D-loop T16519C 52 47 74 50
D-loop A73G 59 91 92 89
D-loop A263G 93 36 60 72
12S rRNA 984 del C1 58 73 72 72
C984G1 16
12S rRNA A1438G 95 91 95 94
tRNAval 1648 del T1 93 98 92 72
tRNAval 1653 del T1 20 98 87 100
T1653A1 76
tRNAval 1659 del T1 89 78 95 94
COX2 8237 del A1 68 82 49 67
ATP6 A8860G 96 96 97 83
ATP6 8877 del T1 49 40 44 78
ATP6 T8889 A1 51 93 87 83
T8889C1 16
8889del T1 24
1 Not reported in mtDNA databank.
The frequency % of the three subtypes at np 984,1653 and 8889 represents the sum total of the different types of mutations occurring at that 
position.
Distributions of the most frequent mtDNA mutations (984delC-12S rRNA; 1648delC, T1653A, 1659delT-tRNAval; 8877delC- ATPase 6; T16519C, A73G, A263G-D-loop region) in three epithelial ovarian tumor subtypes compared to 100 human genome  sequences [24] Figure 1
Distributions of the most frequent mtDNA mutations (984delC-12S rRNA; 1648delC, T1653A, 1659delT-tRNAval; 8877delC-
ATPase 6; T16519C, A73G, A263G-D-loop region) in three epithelial ovarian tumor subtypes compared to 100 human genome 
sequences [24]. Mutation A263G appears to be less frequent in the epithelial ovarian tumor subtypes compared to the general 
population and the mtDNA-tRNAval 1653delT variant may be considered as a causative event for the three epithelial ovarian 
tumor subtypes.
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A. MtDNA sequence electropherograms showing variations in consecutive C-stretch at np 303–310 of the D-loop region  obtained from the three subtypes of the epithelial ovarian neoplasms (a) C6TC6 and (b) C7TC5 sequences from stage I of  endometrioid tumor; (c) C7TC6 and (d) C8TC6 sequences from stage I of mucinous tumor; (e) C9TC6 sequence obtained from  stage III of mucinous tumor; (f) C10TC6 sequence from stage III of serous tumor Figure 2
A. MtDNA sequence electropherograms showing variations in consecutive C-stretch at np 303–310 of the D-loop region 
obtained from the three subtypes of the epithelial ovarian neoplasms (a) C6TC6 and (b) C7TC5 sequences from stage I of 
endometrioid tumor; (c) C7TC6 and (d) C8TC6 sequences from stage I of mucinous tumor; (e) C9TC6 sequence obtained from 
stage III of mucinous tumor; (f) C10TC6 sequence from stage III of serous tumor. Interestingly, the C-stretch instability at np 
303–315 was observed in 97% of our study samples. B. Sequence electropherograms showing the mtDNA instability at np (a) 
309insCT in stage II of endometrioid tumor and (b) 310insTC observed only in early stages of serous subtype in this study. 
Arrow shows the unique 309insCT and 310insTC patterns respectively.
C8TC6 C8TC6
(B)
(a)                                                           (b)
309 ins CT 310 ins TC
C6TC6
C7TC6
C9TC6
C7TC5
C8TC6
C10TC6
(A)
(c)                   (d)
(a)                   (b)
(e)                  (f)Journal of Carcinogenesis 2007, 6:1 http://www.carcinogenesis.com/content/6/1/1
Page 6 of 7
(page number not for citation purposes)
type, at np 1657delC in stage IV (10/10) and 8221delA in
benign cystadenomas (3/3) and borderline tumors (4/4).
To our knowledge, the incidence of specific mtDNA vari-
ants in association with FIGO stages and subtypes of epi-
thelial ovarian tumor have not been reported.
A previous study by Liu et al., [40] reported a high inci-
dence of somatic mtDNA mutations in ovarian carcinoma
and it is consistent with our observation where we
observed somatic mutations in the mtDNA of a majority
of the tumor samples. In contrast to the same study [40],
we did not find an increase or decrease of CA repeats at
514–524, except few ins/del sequence variants with no
significant association with specific ovarian tumor stages,
subtypes or matched normal tissues. Perhaps the discrep-
ancies may be attributed to the histopathologic stages of
the tumor tissues that we analysed and the mtDNA haplo-
group within ovarian cancer.
Conclusion
Notably, most of the identified mtDNA sequence variants
occurred in D-loop region and any mutation in this region
may potentially modify the rate of mtDNA replication.
The D-loop region is important for replication and expres-
sion of mitochondrial genome due to the leading-strand
origin of replication and the promoters of transcription
[41]. Although our study lacks functional data and clinical
outcome of the mitochondrial genome alterations in rela-
tionship to ovarian neoplasms, it suggests that mtDNA
sequence variants may play a role in etiological differ-
ences that may exist between the pathogenicity of sub-
types and stages of benign and invasive epithelial ovarian
tumors. Large population-based studies are required to
precisely quantify the functional role of mtDNA sequence
variants in histological subtypes and stages of ovarian can-
cer. Given that we only sequenced 3.3 kb of 16.5 kb frag-
ment of mitochondrial genome, the level of mtDNA
sequence variants that could be correlated with ovarian
tumor subtypes and stages may far exceed the number we
have observed in this study.
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